Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology

BACKGROUND: Recent clinical evidence showed that breast cancer with low HER2 expression levels responded to trastuzumab deruxtecan therapy. The HER2-low cancers comprise immunohistochemistry (IHC) score 1+ and 2+ ISH non-amplified tumours, currently classified as HER2 negative. Little data exists on...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaakouk, Mohamed, Quinn, Cecily, Provenzano, Elena, Boyd, Clinton, Callagy, Grace, Elsheikh, Soha, Flint, Joe, Millican-Slater, Rebecca, Gunavardhan, Anu, Mir, Yasmeen, Makhija, Purnima, Di Palma, Silvana, Pritchard, Susan, Tanchel, Bruce, Rakha, Emad, Atallah, Nehal M., Lee, Andrew H.S., Pinder, Sarah, Shaaban, Abeer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382984/
https://www.ncbi.nlm.nih.gov/pubmed/37419078
http://dx.doi.org/10.1016/j.breast.2023.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382984/
https://www.ncbi.nlm.nih.gov/pubmed/37419078
http://dx.doi.org/10.1016/j.breast.2023.06.005

Ejemplares similares